Navigation Links
Ampio Announces Positive Preliminary Update on the Optina™ Clinical Trial to Treat Diabetic Macular Edema and Decision to Conclude the Study Ahead of Schedule
Date:3/19/2012

age for the FDA that includes the basic science and clinical results for discussion of the design of a pivotal trial in the US under the 505(b)2 regulation for repurposed drugs. A detailed analysis of the study results will follow pending the completion of data analysis by our CRO."

About Diabetic Retinopathy, Diabetic Macular Edema and current treatments
Dr. David Bar-Or, Chief Scientific Officer of Ampio, noted, "Diabetic retinopathy is damage to the retina of the eyes caused by complications of diabetes mellitus and often resulting in loss of visual acuity and blindness.  Macular edema of the eyes is often an early form of diabetic retinopathy that causes significant vision loss.  Almost all Type 1 diabetics and more than 60% of Type 2 diabetics will develop retinopathy. 

"There is no effective daily drug treatment for diabetic retinopathy other than general measures, such as controlling blood sugar, hypertension, blood lipids, etc.  Due to the global diabetes epidemic, diabetic retinopathy is recognized as a high unmet medical need that would benefit from having oral therapeutic options available. The only treatments available for macular edema now are laser therapy, injection or implantation of drugs into or around the eyeball (not approved in the US or Canada). To our knowledge, Optina™ is the only proposed oral treatment for this condition."

About Optina™
Ampio is developing Optina™, an orally administered ultra low dose of danazol, for the treatment of diabetic macular edema (DME).  Ampio's Chief Scientific Officer discovered an unexpected activity in his investigation of the mechanism of action of danazol: very low doses reversed inflammation induced increases in the permeability of blood vessels, thus reducing vascular leakage.  Dr. Bar-Or subsequently managed in-vitro studies that suggested this effect may reduce the vasogenic edema produced by various vascular le
'/>"/>

SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
2. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
3. Atlanta-based Med Tech Company CardioMEMS Raises Additional Capital to Advance its CHAMPION Clinical Trial for its Wireless Sensor System for Heart Failure Monitoring
4. U.S. Patent Issued for Champions Biotechnologys Lead Oncology Drug
5. Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment of Cancer
6. Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results
7. Chay Enterprises Inc. Completes Merger With Repurposed Drug Developer Ampio Pharmaceuticals, Inc.
8. Ampio Pharmaceuticals, Inc. Retains Redwood Consultants, LLC to Assist in Shareholder Relations and Strategic Planning
9. Ampio Pharmaceuticals to Acquire DMI Biosciences, Inc.
10. Ampio Pharmaceuticals, Inc. Appoints New Chairman and Chief Financial Officer
11. Higher Education Leaders Receive TCWF Champions of Health Professions Diversity Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Orexigen® Therapeutics, Inc. (Nasdaq: OREX ... 2014, on Thursday, August 7, 2014 before markets open. ... and conference call at 8:00 a.m. Eastern time (5:00 ... the call and webcast to discuss financial results and ... by calling (800) 708-4540 (domestic) or (847) 619-6397 (international), ...
(Date:7/31/2014)... Cipla Europe NV ("Cipla") ... entered into a commercial collaboration, covering the territory ... countries, for BioQuiddity,s OneDose ReadyfusOR™ in regional anesthetic ... launch the CE Marked OneDose ReadyfusOR pre-filled with ... market late this year. The ready-to-use infusion systems ...
(Date:7/31/2014)... England , July 31, 2014 ... today announced that its subsidiary, Molecular Profiles Ltd., ... will support pharmaceutical and biotech drug developers during ... pharmaceutical development services will be supported by XenoGesis, ... to give clients a smarter route into formulation ...
Breaking Medicine Technology:Orexigen Therapeutics to Host Second Quarter 2014 Financial Results Conference Call and Webcast 2Cipla and BioQuiddity Announce EU Commercial Partnership for OneDose-ReadyfusOR for Post-Surgical Pain Management 2Cipla and BioQuiddity Announce EU Commercial Partnership for OneDose-ReadyfusOR for Post-Surgical Pain Management 3Columbia Laboratories' Subsidiary, Molecular Profiles, Strikes Alliance With Xenogesis 2Columbia Laboratories' Subsidiary, Molecular Profiles, Strikes Alliance With Xenogesis 3
... Inc. (Nasdaq: ONXX ) today announced the ... proteasome inhibitor, at the American Society of Hematology (ASH) ... Convention Center in Orlando, FL. "The ... treatment option for patients with multiple myeloma, and we ...
... 2010 Decision Resources, one of the world,s leading research ... the acute ischemic stroke (AIS) drug market will remain relatively ... million in 2019 in the United States, France, Germany, Italy, ... 2010 findings from the topic entitled Acute Ischemic Stroke ...
Cached Medicine Technology:Onyx Pharmaceuticals Announces Data Presentations Highlighting Carfilzomib Development Program at 52nd American Society of Hematology Annual Meeting 2Onyx Pharmaceuticals Announces Data Presentations Highlighting Carfilzomib Development Program at 52nd American Society of Hematology Annual Meeting 3Onyx Pharmaceuticals Announces Data Presentations Highlighting Carfilzomib Development Program at 52nd American Society of Hematology Annual Meeting 4Onyx Pharmaceuticals Announces Data Presentations Highlighting Carfilzomib Development Program at 52nd American Society of Hematology Annual Meeting 5The Acute Ischemic Stroke Drug Market Will Remain Relatively Flat, Increasing from $460 Million in 2009 to Approximately $610 Million in 2019 2The Acute Ischemic Stroke Drug Market Will Remain Relatively Flat, Increasing from $460 Million in 2009 to Approximately $610 Million in 2019 3
(Date:7/31/2014)... Randy Dotinga HealthDay Reporter ... parasite that causes malaria is growing increasingly resistant to the ... reports. But several new drugs are in development, and at ... against this global killer. "Although there has been considerable ... against malaria is far from won, and there is still ...
(Date:7/31/2014)... 31, 2014 ReputationChief.Com, a well-recognized ... online reputation management service named ‘Remove Pissed Consumer’. ... organizations get rid of Pissed Consumer Complaints. , ... extensive research. ReputationChief.Com management assigned the responsibility to ... who are struggling in their social or professional ...
(Date:7/31/2014)... July 31, 2014 -- A new study by researchers ... a peptide called caerulein can convert existing cells in ... diabetes-insulin-producing beta cells. The study, published online July 31 ... new approach to treating the estimated 3 million people ... with type 1 diabetes. , "We have found a ...
(Date:7/31/2014)... CA (PRWEB) July 31, 2014 ... healthcare providers, strives in maintaining the highest standards ... That is why Healthpointe is offering Occupational ... surrounding employers, employees and patients. They also accept ... carriers. , Healthpointe’s Occupational Medicine services include, but ...
(Date:7/31/2014)... July 31, 2014 Dallas Fit Body ... Dallas, Texas to 3821 Ross Avenue, also in Dallas, in ... and potential members to burn fat and get in great ... move because he believes that the new space will help ... fitness results they want as well as accommodate new members ...
Breaking Medicine News(10 mins):Health News:Malaria Growing Resistant to Drugs Used to Fight It 2Health News:Malaria Growing Resistant to Drugs Used to Fight It 3Health News:ReputationChief.Com Announces a New Online Reputation Management Service 2Health News:A new way to generate insulin-producing cells in Type 1 diabetes 2Health News:Occupational Medicine Services Available at Healthpointe’s Perris Facility 2Health News:Dallas Fit Body Boot Camp Moves to New Location, Announces Grand Opening Set for Saturday August 9th 2
... Mom,s touch and diet Claire-Dominique Walker, PhD, ... The quality and quantity of maternal milk and maternal-infant ... according to recent research published in Developmental Psychobiology ... early in life can shape the physiology and behaviour ...
... N.C. A multidisciplinary team of University of North Carolina ... grant to develop computer models that will allow physicians to ... airway problems. The three co-principal investigators of the ... Stephanie Davis, MD, Chief of Pediatric Pulmonology in the School ...
... , THURSDAY, Feb. 3 (HealthDay News) -- ... and their doctors better understand the condition, a new ... a personal digital assistant (PDA) device. The patients used ... and other issues three times a day for 30 ...
... ANGELES (Feb. 2, 2011) A team of scientists from ... million grant from the California Institute for Regenerative Medicine ... discoveries for specific diseases. Additionally, another team ... million grant with a medical technology company aiming to develop ...
... HealthDay Reporter , WEDNESDAY, Feb. 2 (HealthDay News) -- ... increasingly common intestinal infection Clostridium difficile , which ... recurrence far better than currently used medications. Researchers ... drug often prescribed to C. difficile patients. ...
... By Maureen Salamon HealthDay Reporter , ... have devised a process to create ready-made, easily stored ... undergoing heart surgery or kidney dialysis. Using donor ... spent more than five years engineering the "off-the-shelf" blood ...
Cached Medicine News:Health News:Brains need love, too 2Health News:UNC researchers developing computer models for pediatric airway problems 2Health News:Cedars-Sinai research team awarded $1.9 million from CIRM to develop new tools and technologies 2Health News:Cedars-Sinai research team awarded $1.9 million from CIRM to develop new tools and technologies 3Health News:New Antibiotic Helps Prevent Recurrence of Dangerous Gut Infection 2Health News:New Antibiotic Helps Prevent Recurrence of Dangerous Gut Infection 3Health News:Researchers Craft Blood Vessels for Heart, Kidney Patients 2Health News:Researchers Craft Blood Vessels for Heart, Kidney Patients 3
... delicate urethral tissues. The gentle, ... provide nearly friction-free movement, without ... to maintain sterility. You simply ... own sterile water, avoiding contamination ...
The Antibacterial Personal Catheter® features a unique silicone composition that provides an antibacterial coated soft outer layer of silicone combined with a firm inner layer....
The Antibacterial Personal Catheter® features a unique silicone composition that provides an antibacterial coated soft outer layer of silicone combined with a firm inner layer....
... Rochester Medical's line of ... intermittent catheters you would ... four product configurations - ... antibacterial hydro - are ...
Medicine Products: